Purpose: The present study aimed to establish an index system for the performance evaluation of specialty nurses (SNs) in tertiary hospitals.
Background: An objective index system for performance evaluation of SN has not yet been established in China.
Design: A 2-round Delphi survey sought opinions from experts about the index system for SNs' performance evaluation in tertiary hospitals in China.
Methods: Delphi survey was used to inquire approximately 20 experts from the fields of nursing management, nursing education, and clinical nursing. We determined the weight coefficient of each index of performance evaluation based on the opinion. Finally, the index of the quality evaluation was established for SN.
Results: A total of 20 experts from 10 provinces in China reached a consensus on the tertiary indexes of the assessment model. The indexes contained first-level (4), second-level (16), and third-level (24) indicators. The 4 aspects of the performance evaluation, including clinical specialist practice assessment, nursing research, education assessment, medical cooperation recognition, and personal comprehensive ability assessment, reached consensus.
Conclusion: Establishing the performance evaluation for SNs aided the SNs in achieving the best clinical practice after training. The performance evaluation still needed to be continuously improved.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/NUR.0000000000000604 | DOI Listing |
Semin Ophthalmol
January 2025
Department of Ophthalmology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Purposes: This meta-analysis aims to systematically analyze the efficacy of low-level red light (LRL) therapy for myopia control and prevention in children.
Methods: All the data were searched from the PubMed, EMBASE, and the Cochrane Library. The Cochrane Handbook was used to evaluate the quality of the included studies.
Jpn J Ophthalmol
January 2025
Department of Ophthalmology, Graduate of Medicine, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Purpose: To assess the efficacy and safety of PreserFlo MicroShunt (PMS) combined with mitomycin C in patients with medically treated primary open-angle glaucoma (POAG).
Study Design: A retrospective observational study.
Methods: The study examined 83 eyes from 83 patients with medically treated glaucoma surgery naive POAG.
Dig Dis Sci
January 2025
Ningxia Medical University, Xing Qing Block, Shengli Street No.1160, Yin Chuan City, 750004, Ningxia Province, People's Republic of China.
Background: Colon adenocarcinoma (COAD) is a leading cause of cancer-related mortality worldwide. Transient receptor potential vanilloid 4 (TRPV4), a calcium-permeable non-selective cation channel, has been implicated in various cancers, including COAD. This study investigates the role of TRPV4 in colon adenocarcinoma and elucidates its potential mechanism via the ferroptosis pathway.
View Article and Find Full Text PDFDig Dis Sci
January 2025
Department of Otorhinolaryngology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Objectives: As one of the most common complications of laryngopharyngeal reflux or gastroesophageal reflux disease, dental erosion presents a significant association with laryngopharyngeal reflux. This study aimed to elucidate the role of laryngopharyngeal reflux and gastroesophageal reflux disease on the severity and occurrence of dental erosion in adult populations.
Methods: A comprehensive search was performed in the databases of PubMed/MEDLINE, Web of Science, Cochrane Library, and Scopus for English literature published from July 1999 to June 2024.
Clin Rheumatol
January 2025
Department of Public Health, University of Murcia, Campus de Ciencias de la Salud, Murcia, 30120, Spain.
Introduction: Therapeutic drug monitoring (TDM) in inflammatory rheumatic diseases (RMDs) is gaining interest. However, there are unresolved questions about the best practices for implementing TDM effectively in clinical settings.
Objective: The primary objective of this study was to evaluate whether early TDM of adalimumab predicts drug survival at 52 weeks in patients with RMDs.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!